By Stephen Nakrosis
Kezar Life Sciences shares were trading higher in Wednesday’s after-hours market, following the entry of an agreement with biotechnology company Everest Medicines to develop and commercialize Zetomipzomib for lupus nephritis and other potential indications in Asia.
Under the terms of the deal, Kezar is eligible to receive…
Read the full article here
